SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


M. Wheeler, P. O’Meara and M. Stanford, “Fetal Methotrexate and Misoprostol Exposure: The Past Revisited,” Teratology, Vol. 66, No. 2, 2002, pp. 73-76. doi:10.1002/tera.10052

has been cited by the following article:

  • TITLE: An Ongoing Epidemic of Birth Defects

    AUTHORS: Gladys Cossio, Alberto Bissot, Mireya de Rivas, Luis Morales, Paul Gallardo, David Ellis, Judith Hal

    KEYWORDS: Congenital Anomalies; Teratogenic Agent; Misoprostol; Pregnancy

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.3, June 4, 2013

    ABSTRACT: In the 1990s, misoprostol (synthetic prostaglandin E1 analogue) was found to be an effective abortive agent when taken orally and became widely used in Latin America as a means to terminate unwanted pregnancies. A variety of congenital anomalies have been observed among the children of women who ingested misoprostol, but failed to terminate their pregnancy. We report here eight years of experience in Panama with the detection and follow-up of the malformations seen in infants associated with the use of misoprostol prostaglandin during the first trimester of pregnancy. During the period between April 1995 and March 2003, we identified 63 infants at the Panama’s Children’s Hospital who were exposed to misoprostol while in the womb and who were born with malformations. These infants were evaluated by a team of neonatologists, geneticists, cardiologists, ophthalmologists, and radiologists.